Skip to content
Cancer treatment monitoring is the process of tracking how a tumour responds to therapy across a series of scans over weeks and months. It is one of the most consequential parts of cancer care, yet it receives far less attention than the first diagnosis. How do you know whether your treatment is working? And how reliable is the judgement that a tumour has shrunk, stayed the same, or grown? This guide explains how monitoring works, why it is more difficult than it appears, and how an independent second opinion on follow-up scans can add confidence at the moments when it matters most.
When you are first diagnosed, attention naturally focuses on getting the diagnosis right. Once treatment begins, the question quietly shifts. Every few weeks or months, a new scan is compared with the last, and someone has to decide what the change means. That judgement guides whether you continue a therapy, switch to another, add a treatment, or step back. Because so much rests on these comparisons, the consistency and quality of the reading deserve the same care that went into the original diagnosis.
What cancer treatment monitoring actually measures
Monitoring cancer treatment with imaging is built on measured change rather than a single snapshot. Radiologists select a small number of measurable tumours, known as target lesions, and track their size on each follow-up scan. The most widely used framework for solid tumours is RECIST version 1.1, which translates these measurements into four broad categories: complete response, partial response, stable disease, and progressive disease (European Society of Oncologic Imaging, 2023).
In practice, the radiologist measures the longest diameter of each target lesion, adds the measurements together, and compares the sum with previous scans. A meaningful decrease suggests the treatment is shrinking the cancer. A meaningful increase, or the appearance of new lesions, suggests progression. Stable disease sits in between, where the tumour is neither clearly shrinking nor clearly growing.
Different cancers and different treatments call for different tools. CT is the workhorse for chest and abdominal monitoring, MRI is preferred for the brain, liver, and pelvis, and FDG-PET/CT can reveal metabolic activity before a tumour changes in size (PERCIST interrater study, 2020). The choice of modality, the timing of scans, and the criteria applied all influence the final assessment, which is why an experienced oncological radiologist is central to accurate, reproducible monitoring (International Cancer Imaging Society).
Why cancer treatment monitoring is harder than it looks
Comparing two scans sounds straightforward, but tumour measurement carries genuine uncertainty. Studies of measurement variability have found that the same lesion measured by two different radiologists can differ by roughly 10 to 25 per cent, and that this variability can occasionally push a case across the boundary between response categories (observer-variability analysis, 2022). In other words, two careful, well qualified radiologists can occasionally reach different conclusions about whether a tumour has truly changed.
This is not a sign that anyone is careless. It reflects the nature of the task. Tumour edges can be irregular and hard to define, a lesion that is easy to measure on one scan can be obscured on the next, and the choice of which lesions to follow is itself a judgement. Research in lung cancer has shown that these measurement differences between observers can lead to different classifications of response or progression in a proportion of cases (Erasmus et al., 2003).
Newer treatments add further complexity. Immunotherapy can cause a tumour to appear larger or show new spots before it begins to shrink, a pattern known as pseudoprogression, which a size-only rule can misread as failure. Targeted and cytostatic drugs may halt growth without producing the dramatic shrinkage that older chemotherapy aimed for, so a tumour that is stable in size may in fact represent a good response. Recognising these patterns requires familiarity with the specific treatment, not just the measuring tape.
How a second opinion strengthens cancer treatment monitoring
A second opinion during treatment is not about deciding that the first radiologist was wrong. It is about consistency, context, and confidence. An independent subspecialty radiologist re-measures the target lesions, applies the response criteria carefully, and assesses whether the reported change is robust or borderline. When the two readings agree, you gain reassurance. When they differ, you and your oncology team have a clearer basis for an important conversation.
There are several specific ways a second read helps. It can confirm whether an apparent change crosses a real threshold or sits within measurement noise. It can flag when a different modality, such as PET or MRI, would answer the question more reliably than the scan in front of you. And it can bring pattern recognition to confusing situations, such as distinguishing genuine progression from immunotherapy related pseudoprogression, where the right interpretation changes the entire plan.
The downstream effect on decisions can be significant. A study of patients who sought a cancer second opinion found that about one in three had a change in their recommended treatment, and that the change was most often toward a less intense regimen rather than a more aggressive one (Roman BR et al., 2023). For someone weighing whether to continue a demanding therapy, that kind of clarity is not a luxury. It can mean avoiding treatment that is no longer helping, or continuing one that is working better than a single reading suggested.
When a second opinion helps most during treatment
A second opinion on follow-up scans is most useful at decision points rather than at every routine scan. The clearest moments are when a scan is reported as showing progression and your team is considering stopping or switching treatment, because that is a high stakes decision built directly on the imaging. A second read is also valuable when results seem inconsistent with how you feel, when an immunotherapy scan is ambiguous, or when a major step such as surgery or a change of regimen depends on the interpretation.
It is equally reasonable to seek a second opinion simply for peace of mind at a pivotal point in a long treatment journey. If you are unsure how to read a follow-up report, our guide on «What Is a Radiology Second Opinion? A Complete Guide» explains the basics, and «Second Opinion Before Surgery» covers the related situation where an operation is on the table. Knowing that your scans have been independently reviewed by a subspecialty radiologist can make difficult choices feel less uncertain.
For many patients, the value is not in changing the plan but in confirming it. A concordant second opinion allows you to commit to your treatment with confidence, knowing that the assessment of how it is working has been checked by a second experienced set of eyes.
⚠ Key Considerations
Monitoring is about measured change over time, not a single image, and small differences between scans do not always mean a real change in the disease.
Tumour measurement carries real interobserver variability, so two qualified radiologists can occasionally classify the same scan differently without either being careless.
A second opinion during treatment is most valuable at decision points, especially when a scan is reported as progression or when immunotherapy results are ambiguous.
A second read often confirms the existing plan; when it does change management, the change is frequently toward less intensive rather than more aggressive treatment.
Frequently asked questions
How is cancer treatment monitored with scans?
Cancer treatment monitoring uses a series of scans taken at intervals, usually every two to three months for many solid tumours, that are compared with earlier images. A radiologist measures selected target lesions and applies response criteria such as RECIST 1.1 to decide whether the cancer has responded, stayed stable, or progressed. The pattern across several time points, not just the latest scan, gives the most reliable picture of how treatment is working.
How often are follow-up scans done during cancer treatment?
The timing depends on the cancer type, the treatment, and your oncology team’s protocol, but many regimens schedule imaging roughly every two to three months during active treatment. After treatment, surveillance scans are usually spaced further apart. Your oncologist sets the schedule based on guidelines and your individual situation, and a second opinion does not change that schedule, it simply adds an independent reading of the scans you already have.
Can a second opinion change my cancer treatment plan?
It can, although a confirmation of the existing plan is a common and valuable outcome. Research on cancer second opinions found that about one in three patients had a change in recommended treatment, most often toward a less intense regimen. A second opinion on follow-up scans gives your treating team additional information, and any decision to adjust treatment remains with you and your oncologist.
Why do two radiologists sometimes disagree on whether a tumour has shrunk?
Tumour measurement is partly a matter of judgement, because lesion edges can be irregular, lesions can be harder to see on one scan than another, and radiologists may select slightly different target lesions to follow. Studies have measured this interobserver variability at roughly 10 to 25 per cent for individual lesions. This is a normal feature of imaging, and it is precisely why an independent second measurement can be reassuring when a result sits near a decision threshold.
Which scan is best for monitoring my treatment response?
There is no single best scan for every situation. CT is commonly used for the chest and abdomen, MRI is preferred for the brain, liver, and pelvis, and FDG-PET/CT can detect changes in metabolic activity that size measurements alone may miss. Part of the value of a subspecialty second opinion is judging whether the modality you are using is the most informative one for your specific cancer and treatment.
Conclusion
Cancer treatment monitoring is where the real work of cancer care often happens, quietly, scan by scan, over months of treatment. Because so many decisions rest on the comparison between one scan and the next, and because that comparison carries genuine measurement uncertainty, the quality and consistency of the reading matter enormously. An independent second opinion on your follow-up scans will not replace your oncology team, and it does not imply that anyone made a mistake. What it offers is confidence: a second experienced radiologist confirming what your scans show, or giving you and your doctors a clearer basis for an important decision.
If you have questions about your scan, speak with a specialist radiologist.
Sources
PERCIST interrater study, 2020. Agreement using FDG-PET/CT in metastatic breast cancer.
Roman BR et al., 2023 (Cancer Medicine), reported by Memorial Sloan Kettering.
World Health Organization. Cancer fact sheet.
This article is for general information and patient education only. It does not constitute medical advice and is not a substitute for consultation with your treating physician or oncology team. Always discuss your individual situation and any decisions about your care with a qualified healthcare professional.